Compare NIE & VIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NIE | VIR |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 718.5M | 825.0M |
| IPO Year | N/A | 2019 |
| Metric | NIE | VIR |
|---|---|---|
| Price | $25.42 | $6.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.73 |
| AVG Volume (30 Days) | 70.5K | ★ 2.1M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 9.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $16,860,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $48.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $18.61 | $4.16 |
| 52 Week High | $22.47 | $14.45 |
| Indicator | NIE | VIR |
|---|---|---|
| Relative Strength Index (RSI) | 55.37 | 49.41 |
| Support Level | $25.10 | $5.73 |
| Resistance Level | $25.07 | $6.11 |
| Average True Range (ATR) | 0.27 | 0.39 |
| MACD | 0.03 | -0.08 |
| Stochastic Oscillator | 77.61 | 28.57 |
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.